<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01246635</url>
  </required_header>
  <id_info>
    <org_study_id>CSA-2005-02</org_study_id>
    <nct_id>NCT01246635</nct_id>
  </id_info>
  <brief_title>Smith &amp; Nephew's European Trufit Study</brief_title>
  <official_title>A Prospective, Multi-Center, Randomized, Single-Blind, Controlled Study Comparing the Trufit CB (Cartilage Bone) Implant to Microfracture for the Treatment of Patients With Single, Isolated Defects of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Smith &amp; Nephew, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Smith &amp; Nephew, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to demonstrate the effectiveness and safety of the&#xD;
      Trufit CB (Cartilage Bone) implant for the treatment of single, isolated cartilage defects of&#xD;
      the knee compared to Microfracture.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 315 subjects, ages 18 years and older with a single, isolated cartilage defect of the&#xD;
      knee will be randomized in a 1:1:1 ratio to 1 of 3 treatment groups:&#xD;
&#xD;
        -  Trufit CB Implant with rehabilitation protocol;&#xD;
&#xD;
        -  Trufit CB Implant with rehabilitation protocol;&#xD;
&#xD;
        -  Microfracture with rehabilitation protocol&#xD;
&#xD;
      Rehabilitation program may be standard (6 weeks touch weight to full weight bearing) or&#xD;
      accelerated (2 weeks touch weight to full weight bearing).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated early due to slow and insufficient total enrollment.&#xD;
  </why_stopped>
  <start_date type="Actual">April 15, 2008</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in the Knee injury and Osteoarthritis Outcome Score (KOOS) from baseline</measure>
    <time_frame>6 months post-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent improvement from baseline in the KOOS Knee Survey Score at all time-points</measure>
    <time_frame>2 weeks, 6, weeks, 3 months, (6 months - primary measure), 12 months and 24 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive change in activity level from baseline to each visit, as measured by the Tegner Activity Scale at all time-points.</measure>
    <time_frame>2 weeks, 6 weeks, 3 months, 6 months, 12 months and 24 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in Pain Scores on the Visual Analog Scale from baseline at all post operative time-points.</measure>
    <time_frame>2 weeks, 6 weeks, 3 months, 6 months, 12 months and 24 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic resonance evaluation of cartilage and underlying bone using the MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) scale</measure>
    <time_frame>12 and 24 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects (compared to baseline) with cartilage classifications within the four groups defined by the International Cartilage Repair Society (ICRS) scoring system</measure>
    <time_frame>24 months post-procedure</time_frame>
    <description>Evaluation of cartilage at 24 months post-procedure will only occur for subjects who consent to a second-look biopsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological evaluation of cartilage</measure>
    <time_frame>24 months post-procedure</time_frame>
    <description>Histological characterization of cartilage will only occur for those subjects consenting to both the second look arthroscopy and biopsy at 24-months post-procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>2 weeks, 6 weeks, 3 months, 6 months, 12 months and 24 months post-procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Defect of Articular Cartilage</condition>
  <arm_group>
    <arm_group_label>TRUFIT CB with accelerated rehab.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TRUFIT CB with standard rehab.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>• Microfracture with rehabilitation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Trufit CB (Cartilage Bone) Implant</intervention_name>
    <description>Implantation of 5,7, 9, or 11 mm Trufit CB Implants for small cartilage lesions. A maximum of two Trufit CB plugs may be implanted.</description>
    <arm_group_label>TRUFIT CB with accelerated rehab.</arm_group_label>
    <arm_group_label>TRUFIT CB with standard rehab.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microfracture if the knee</intervention_name>
    <description>Creation of small holes through subchondral bone with the goal of stimulating cartilage growth</description>
    <arm_group_label>• Microfracture with rehabilitation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Capable of providing informed consent;&#xD;
&#xD;
          -  Eighteen (18) years or older and skeletally mature on the date of study enrollment;&#xD;
&#xD;
          -  Willing and able to attend all follow up visits and complete all study related&#xD;
             procedures and evaluations including, but not limited to adhering to the&#xD;
             rehabilitation protocol;&#xD;
&#xD;
          -  Single, isolated cartilage defect (ICRS Grade III - IV) in the knee (medial or lateral&#xD;
             femoral condyle or trochlea) that is ≥ 1cm2 (10 mm) and ≤ 2cm2 (20 mm) in area and&#xD;
             requiring a maximum of 2 implants (if randomized to TRUFIT CB); Note: Lesion size&#xD;
             should be assessed as the product of the longest diameter and its perpendicular&#xD;
             applied at the widest portion of the lesion.&#xD;
&#xD;
          -  Candidate for cartilage repair surgery as a result of a single, isolated symptomatic&#xD;
             cartilage lesion;&#xD;
&#xD;
          -  Presents with stable health at the time of study enrollment;&#xD;
&#xD;
          -  BMI of ≤ 32.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female of child-bearing potential who is pregnant or plans to become pregnant over the&#xD;
             course of the study;&#xD;
&#xD;
          -  History of alcohol or drug abuse;&#xD;
&#xD;
          -  Presents with patellofemoral instability or other anatomical malalignment in the study&#xD;
             knee;&#xD;
&#xD;
          -  Any diagnosis that would preclude the patient from successfully completing the study&#xD;
             rehabilitation protocols;&#xD;
&#xD;
          -  Unable or unwilling to follow post operative procedures (e.g. rehabilitation&#xD;
             protocol);&#xD;
&#xD;
          -  Received one or more intra-articular steroid injections in the study knee within the&#xD;
             previous 3 months;&#xD;
&#xD;
          -  Presents with ipsilateral hip disease, as determined by pain or restricted range of&#xD;
             motion upon physical examination;&#xD;
&#xD;
          -  Treated with either an investigational device or drug within one (1) month of study&#xD;
             enrollment, or plans to be treated with an investigational device or drug in the next&#xD;
             24 months;&#xD;
&#xD;
          -  Diagnosed rheumatoid arthritis, ankylosing spondylitis (Bechterew syndrome), or&#xD;
             calcium pyrophosphate dihydrate disease(chondrocalcinosis);&#xD;
&#xD;
          -  History of severe vascular or neurological disease, uncontrolled diabetes, or is&#xD;
             immunosuppressed (e.g. HIV positive);&#xD;
&#xD;
          -  Musculoskeletal disease, including degenerative bone diseases such as osteochondritis&#xD;
             dissecans and osteonecrosis;&#xD;
&#xD;
          -  Pathologic conditions of the bone (e.g. osteoporosis, cystic changes,&#xD;
             hyperparathyroidism, Paget's Disease, hypercalcemia, prolonged use of steroids);&#xD;
&#xD;
          -  Active infection, or evidence thereof, at the lesion site;&#xD;
&#xD;
          -  Requires the use of any medication(s) or treatment(s) known to have an effect on bone&#xD;
             metabolism (e.g. bisphosphonates, chemotherapeutic or immunosuppressive agents);&#xD;
&#xD;
          -  Requires concomitant osteotomy, partial lateral meniscectomy or complete meniscectomy;&#xD;
             Note: Concomitant ACL reconstruction or revision, as well as meniscal repair and&#xD;
             partial medial meniscectomies are permitted under the study protocol.&#xD;
&#xD;
          -  Has undergone an ACL reconstruction, osteotomy, chondral resurfacing procedure or&#xD;
             partial meniscectomy (≤ central third of the meniscus) in the last year and has not&#xD;
             completed at least 6 months of rehabilitation since such surgery; Note: Patients who&#xD;
             have undergone these procedures within the last year and have completed at least 6&#xD;
             months of rehabilitation are eligible to participate in the study.&#xD;
&#xD;
          -  Any active, implanted medical device (e.g. cochlear implant) or metallic implant&#xD;
             (other then dental work) that may interfere with Magnetic Resonance Imaging (MRI);&#xD;
&#xD;
          -  Any condition (e.g. claustrophobia) that may interfere with the patient's ability to&#xD;
             undergo MRI;&#xD;
&#xD;
          -  Diagnosis requiring placement of an active implant (e.g. cardiac pacemaker, vagus&#xD;
             nerve stimulator, etc.) within the next 24 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Karl Brabants, MD</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prof. Dr. K.F. Almqvist</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toon Claes, MD</name>
      <address>
        <city>Herentals</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johan Vanlauwe</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aalborg Private Hospital A/S</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Holz, MD</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kevin J. Mulhall</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sander Koeter, MD</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kees van Egmond, MD</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lars Engebretsen, MD</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magnus Forssblad, MD</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Angus Robertson, MD</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tim Spalding, MD</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Chesney</name>
      <address>
        <city>Fife Keith</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 14, 2010</study_first_submitted>
  <study_first_submitted_qc>November 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2010</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cartilage Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

